– USA, MA – Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced the appointment of Anne Prener, M.D., Ph.D., to its Board of Directors.
Dr. Prener has more than 25 years of leadership experience within life sciences companies and recently served as CEO, Freeline Ltd.
“We are thrilled to welcome Anne to our Board. She brings extensive experience in clinical development and commercialization in multiple therapeutic areas, which will be instrumental to Kaleido as we continue to advance our pipeline of Microbiome Metabolic Therapies,” said Michael Bonney, Executive Chair.
About Dr Anne Prener
Dr. Prener has led companies and teams across several therapeutic areas, including a focus on rare diseases. As CEO of Freeline, a liver-directed gene therapy company, she scaled the company from preclinical stage to a fully integrated biotechnology organization, which included a broad, internally developed pipeline, two programs in clinical development and a commercial-scale, high-quality CMC and manufacturing platform. Prior to joining Freeline, she served as CEO of Gyroscope Therapeutics Ltd., a gene therapy company focused on eye diseases. Before that, Dr. Prener was Global Therapeutic Area Head of Hematology and Vice President, Clinical Research Hematology at Baxalta. During her time there, three new major product approvals in the U.S. and EU were secured along with significant advancement in Baxalta’s hematology portfolio. Earlier in her career, Dr. Prener held several positions of increasing responsibility at Novo Nordisk, most recently serving as Senior Vice President, Hemophilia R&D Portfolio, where she was instrumental in building a portfolio of late-stage and commercial hemophilia products.
Dr. Prener serves on the Boards of Directors of several life-science companies, Rubius Therapeutics, Cellinta and Renovacor.
“With its differentiated approach to the microbiome and compelling human-centric discovery and development, Kaleido has the opportunity to redefine how we manage health and treat a broad range of diseases to impact patients’ lives. I look forward to working with the Board and talented leadership team as Kaleido continues to progress its programs and overall business,” said Dr. Prener.
She holds a Ph.D. in epidemiology and an M.D., both from the University of Copenhagen.
About Kaleido Biosciences
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health. The Company has built a human-centric proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies. MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs.
For more information: https://kaleido.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.